HPV CD8+ T-cell epitopes

Details HPV CD8+ T-cell epitopes HPV CD8+ T-cell epitopes

2006-12-26

2006-12-26

Salimi, Ali R. (Department: 1648)

Chemistry: molecular biology and microbiology

Measuring or testing process involving enzymes or...

Involving nucleic acid

C435S325000, C435S235100

Reexamination Certificate

active

07153659

ABSTRACT:
The present invention provides means to identify functional CD8+ T-cell epitopes in any protein of interest. The present invention further provides CD8+ T-cell epitopes of various proteins. In additional embodiments, the present invention provides epitopes suitable for use in prophylactic and/or therapeutic vaccines. In particularly preferred embodiments, the present invention provides modified epitopes suitable for use in prophylactic and/or therapeutic vaccines.In some preferred embodiments, the present invention provides means for the development of HPV vaccines, in particular multivalent vaccines for the prevention of infection with high-risk HPV strains. In particular, the present invention provides means to identify CD8+ T-cell epitopes in HPV strains such as HPV 16 and HPV 18. In additional embodiments, the present invention provides means for the development of therapeutic vaccines against high-risk HPV types that prevent the development of benign and/or malignant tumors in infected individuals. The present invention further provides epitopes suitable for use in prophylactic and therapeutic vaccines.

REFERENCES:
patent: 4683195 (1987-07-01), Mullis et al.
patent: 4683202 (1987-07-01), Mullis
patent: 4722848 (1988-02-01), Paoletti et al.
patent: 4965188 (1990-10-01), Mullis et al.
patent: 5580859 (1996-12-01), Felgner et al.
patent: 5589466 (1996-12-01), Felgner et al.
patent: 5679647 (1997-10-01), Carson et al.
patent: 5736524 (1998-04-01), Content et al.
patent: 5739118 (1998-04-01), Carrano et al.
patent: 5804566 (1998-09-01), Carson et al.
patent: 5922687 (1999-07-01), Mann et al.
patent: 6962790 (2005-11-01), Ennis
patent: 2001/0055752 (2001-12-01), Ennis
patent: 2002/0137720 (2002-09-01), Ertl et al.
patent: 2002/0187131 (2002-12-01), Hawiger et al.
patent: WO 98/04720 (1998-02-01), None
International Search Report for PCT/US04/27263 filed Aug. 23, 2004.
Addo, M. M. et al., “Comprehensive Epitope Analysis of Human Immunodeficiency Virus Type 1 (HIV-1)-Specific T-Cell Responses Directed against the Entire Expressed HIV-1 Genome Demonstrate Broadly Directed Responses, but No Correlation to Viral Load,”Journal of Virology, 77(3):2081-2092, 2003.
Allen, P. M. et al., “T-Cell Recognition of Lysozyme: The Biochemical Basis of Presentation,”Immunological Reviews, 98:171-187, 1987.
Alonso, M. J. et al., “Biodegradable microspheres as controlled-release tetanus toxoid delivery systems,”Vaccine, 12(4):299-306, 1994.
Altman, J. D. et al., “Phenotypic Analysis of Antigen-Specific T Lymphocytes,”Science, 274:94-96, 1996.
Altschul, S. F. et al., “Basic Local Alignment Search Tool,”J. Mol. Bio., 215:403-410, 1990.
Altschul, S. F. et al., “Local Alignment Statistics,”Methods in Enzymology, 266:460-480, 1996.
Bennett, S. R. M. et al., “Help for cytotoxic-T-cell responses is mediated by CD40 signalling,”Nature, 393:478-480, 1998.
Chakrabarti, S. et al., “Expression of the HTLV-III envelope gene by a recombinant vaccinia virus,”Nature, 320:535-546, 1986.
Chamberlin M. et al., “New RNA Polymerase fromEscherichia collinfected with Bacteriophage T7,”Nature, 228:227-231, 1970.
Chanda, P. K. et al., “High Level Expression of the Envelope Glycoproteins of the Human Immunodeficiency Virus Type I in Presence of rev Gene Using Helper-Independent Adenovirus Type 7 Recombinants,”Virology, 175:535-547, 1990.
Devereux, J. et al., “A comprehensive set of sequence analysis programs for the VAX,”Nucleic Acids Research, 12(1):387-395, 1984.
De Veerman, M. et al., “Retrovirally Transduced Bone Marrow-Derived Dendritic Cells Require CD4+T Cell Help to Elicit Protective and Therapeutic Antitumor Immunity,”J. Immunol., 162:144-151, 1999.
**Dictionary of Microbiology and Molecular Biology, 2d Ed. John Wiley and Sons, NY, 1994.
Eldridge, J. H. et al., “Biodegradable Microspheres as a Vaccine Delivery System,”Molecular Immunology, 28(3):287-294, 1991.
Eldridge, J. H. et al., “New Advances in Vaccine Delivery Systems,”Seminars in Hematology, 30(4):16-25, 1993.
Erratum atScience, 280:1821, 1998.
Falo, L. D. et al., “Targeting antigen into the phagocytic pathwayin vivoinduces protective tumour immunity,”Nature Medicine, 1(7):649-653, 1995.
Feng, Da-Fei, “Progressive Sequence Alignment as a Prerequisite to Correct Phylogenetic Trees,”Journel of Molecular Evolution, 25:351-360 (1987).
Finzer, P. et al., “The role of human papillomavirus oncoproteins E6 and E7 in apoptosis,”Cancer Letters, 188:15-24, 2002.
**Hale and Marham,The Harper Collins Dictionary of Biology, Harper Perennial, NY, 1991.
Henikoff, S. et al., “Amino acid substitution matrices from protein blocks,”Proc. Natl. Acad. Sci. USA, 89:10915-10919, 1992.
Gupta, R. K. et al., “Adjuvants—a balance between toxicity and adjuvanticity,”Vaccine, 11(3):293-306, 1993.
Higgins, D. G. et al., “CLUSTAL: a package for performing multiple sequence alignment on a microcomputer,”Gene, 73:237-244, 1988.
Higgins, D. G. et al., “Fast and sensitive multiple sequence alignments on a microcomputer,”Cabios Communications, 5(2):151-153, 1989.
Hu, K.-F. et al., “The immunostimulating complex (ISCOM) is an efficient mucosal delivery system for respiratory syncytial virus (RSV) envelope antigens inducing high local and systemic antibody responses,”Clin. Exp. Immunol., 113:235-243, 1998.
Hu, Shiu-Lok et al., “Expression of AIDS virus envelope gene in recombinant vaccinia viruses,”Nature, 320:537-543, 1986.
Jones, D. H. et al., “Protection of mice fromBordetella pertussisrespiratory infection using microencapsulated pertussis fimbriae,”Vaccine, 13(7):675-681, 1995.
Kacian, D. L. et al., “A Replicating RNA Molecule Suitable for a Detailed Analysis of Extracellular Evolution and Replication,”Proc. Nat. Acad. Sci. USA, 69(10):3038-3042, 1972.
Kieny, M. P. et al., “Aids Virus ENV protein Expressed From a Recombinant Vaccinia Virus,”Bio/Technology, 4:790-795, 1988.
Kofler, N. et al., Preparation and characterization of poly-(D,L-lactide-co-glycolide) and poly-(L-lactic acid) microspheres with entrapped pneumotropic baterial antigens,Journal of Immunological Methods, 192:25-35, 1996.
Lorincz, A. T., “Human Papillomavirus Infection of the Cervix: Relative Resk Associations of 15 Common Anogenital Types,”Obstetrics&Gynecology, 79(3):328-337, 1992.
Maeji, N. J. et al., “Multi-pin peptide synthesis strategy for T cell determinant analysis,”Journal of Immunological Methods, 134:23-33, 1990.
Nakagawa, M. et al., “Cytotoxic T Lymphocyte Responses to E6 and E7 Proteins of Human Papillomavirus Type 16: Relationship to Cervical Intraepithelial Neoplasia,”Journal of Infectious Diseases, 175:927-931, 1997.
Needleman, S. B. et al., “A General Method Applicable to the Search for Similarities in the Amino Acid Sequence of Two Proteins,”J. Mol. Biol., 48:443-453, 1970.
Nussbaum, A. K. et al., “Using the World Wide Web for predicting CTL epitopes,”Current Opinion in Immunology, 15:69-74, 2003.
Osen, W. et al., “A DNA vaccine based on a shuffled E7 oncogene of the human papillomavirus type 16 (HPV 16) induces E7-specific cytotoxic T cells but lacks transforming activity,”Vaccine, 19:4276-4286, 2001.
Ossendorp, F. et al., “Specific T Helper Cell Requirement for Optimal Induction of Cytotoxic T Lymphocytes against Major Histocompatibility Complex Class II Negative Tumors,”J. Exp. Med., 187(5):693-702, 1998.
Pearson, W. R. et al., “Improved tools for biological sequence comparison,”Proc. Natl. Acad. Sci. USA, 85:2444-2448, 1988.
Perkus, M. E. et al., “Recombinant Virus as Vaccination Carrier of Heterologous Antigens,”Concepts in Vaccine Development, Kaufinann (ed.), 1996.
Reddy, R. et al., “In Vivo Cytot

Affiliated with

Also associated with

Rating

HPV CD8+ T-cell epitopes does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with HPV CD8+ T-cell epitopes, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and HPV CD8+ T-cell epitopes will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3704952